Cross, Robert W.
Mire, Chad E.
Feldmann, Heinz
Geisbert, Thomas W.
Article History
First Online: 29 January 2018
Change Date: 20 April 2018
Change Type: Correction
Change Details: The discussion of the phase II trial of TKM-130803 reported in reference 156 has been revised to correct inaccuracies in the original text.
Competing interests
: T.W.G. and H.F. are listed on several patents and/or patent applications for a number of vaccines and treatments for filoviruses. These patents were related to work performed as official duties when T.W.G. was employed by the US Department of Defense and when H.F. was employed by the Public Health Agency of Canada. T.W.G. and H.F. have not received any royalties related to any filovirus vaccine or treatment patents. T.W.G. receives grants related to filovirus research from the US National Institutes of Health (HHSN261200800001E, R01AI09894301, R01AI09881701, U19AI109711, U19AI109945 and R01AI119185) and the US Department of Defense (W911QY-14-1-001, HDTRA1-12-1-0051 and HDTRA1-17-C-0009).
Free to read: This content has been made available to all.